JP2021502826A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502826A5
JP2021502826A5 JP2020544382A JP2020544382A JP2021502826A5 JP 2021502826 A5 JP2021502826 A5 JP 2021502826A5 JP 2020544382 A JP2020544382 A JP 2020544382A JP 2020544382 A JP2020544382 A JP 2020544382A JP 2021502826 A5 JP2021502826 A5 JP 2021502826A5
Authority
JP
Japan
Prior art keywords
ddpp
seq
domain
amino acid
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544382A
Other languages
English (en)
Japanese (ja)
Other versions
JP7285267B2 (ja
JP2021502826A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/060887 external-priority patent/WO2019099433A2/en
Publication of JP2021502826A publication Critical patent/JP2021502826A/ja
Publication of JP2021502826A5 publication Critical patent/JP2021502826A5/ja
Priority to JP2023050785A priority Critical patent/JP7470840B2/ja
Application granted granted Critical
Publication of JP7285267B2 publication Critical patent/JP7285267B2/ja
Priority to JP2024062058A priority patent/JP7779944B2/ja
Priority to JP2025200748A priority patent/JP2026035661A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544382A 2017-11-14 2018-11-14 Dドメイン含有ポリペプチドおよびその使用 Active JP7285267B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023050785A JP7470840B2 (ja) 2017-11-14 2023-03-28 Dドメイン含有ポリペプチドおよびその使用
JP2024062058A JP7779944B2 (ja) 2017-11-14 2024-04-08 Dドメイン含有ポリペプチドおよびその使用
JP2025200748A JP2026035661A (ja) 2017-11-14 2025-11-20 Dドメイン含有ポリペプチドおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762585780P 2017-11-14 2017-11-14
US62/585,780 2017-11-14
PCT/US2018/060887 WO2019099433A2 (en) 2017-11-14 2018-11-14 D-domain containing polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023050785A Division JP7470840B2 (ja) 2017-11-14 2023-03-28 Dドメイン含有ポリペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2021502826A JP2021502826A (ja) 2021-02-04
JP2021502826A5 true JP2021502826A5 (cg-RX-API-DMAC10.html) 2021-12-23
JP7285267B2 JP7285267B2 (ja) 2023-06-01

Family

ID=66540398

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020544382A Active JP7285267B2 (ja) 2017-11-14 2018-11-14 Dドメイン含有ポリペプチドおよびその使用
JP2023050785A Active JP7470840B2 (ja) 2017-11-14 2023-03-28 Dドメイン含有ポリペプチドおよびその使用
JP2024062058A Active JP7779944B2 (ja) 2017-11-14 2024-04-08 Dドメイン含有ポリペプチドおよびその使用
JP2025200748A Pending JP2026035661A (ja) 2017-11-14 2025-11-20 Dドメイン含有ポリペプチドおよびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023050785A Active JP7470840B2 (ja) 2017-11-14 2023-03-28 Dドメイン含有ポリペプチドおよびその使用
JP2024062058A Active JP7779944B2 (ja) 2017-11-14 2024-04-08 Dドメイン含有ポリペプチドおよびその使用
JP2025200748A Pending JP2026035661A (ja) 2017-11-14 2025-11-20 Dドメイン含有ポリペプチドおよびその使用

Country Status (25)

Country Link
US (2) US11377482B2 (cg-RX-API-DMAC10.html)
EP (2) EP4600353A3 (cg-RX-API-DMAC10.html)
JP (4) JP7285267B2 (cg-RX-API-DMAC10.html)
KR (2) KR102975783B1 (cg-RX-API-DMAC10.html)
CN (1) CN111727250A (cg-RX-API-DMAC10.html)
AU (3) AU2018369639C1 (cg-RX-API-DMAC10.html)
BR (1) BR112020009136A2 (cg-RX-API-DMAC10.html)
CA (1) CA3082406A1 (cg-RX-API-DMAC10.html)
DK (1) DK3710067T3 (cg-RX-API-DMAC10.html)
EA (1) EA202091198A1 (cg-RX-API-DMAC10.html)
ES (1) ES3037854T3 (cg-RX-API-DMAC10.html)
FI (1) FI3710067T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20251027T1 (cg-RX-API-DMAC10.html)
HU (1) HUE072654T2 (cg-RX-API-DMAC10.html)
IL (2) IL274652B2 (cg-RX-API-DMAC10.html)
LT (1) LT3710067T (cg-RX-API-DMAC10.html)
MX (2) MX2020004933A (cg-RX-API-DMAC10.html)
PH (1) PH12020550240A1 (cg-RX-API-DMAC10.html)
PL (1) PL3710067T3 (cg-RX-API-DMAC10.html)
PT (1) PT3710067T (cg-RX-API-DMAC10.html)
RS (1) RS67119B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202003169XA (cg-RX-API-DMAC10.html)
SI (1) SI3710067T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202500422T1 (cg-RX-API-DMAC10.html)
WO (1) WO2019099433A2 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201708257UA (en) 2015-04-06 2017-11-29 Subdomain Llc De novo binding domain containing polypeptides and uses thereof
SI3710067T1 (sl) * 2017-11-14 2026-01-30 Arcellx, Inc. Polipeptidi, ki vsebujejo D-domeno, in njihova uporaba
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
AU2018368431B2 (en) 2017-11-14 2024-03-21 Arcellx, Inc. Multifunctional immune cell therapies
BR112023019689A2 (pt) * 2021-03-26 2023-10-31 Arcellx Inc Terapias multifuncionais de célula imunológica
US20230241118A1 (en) 2021-10-20 2023-08-03 University Of Rochester Rejuvenation treatment of age-related white matter loss
CA3236365A1 (en) 2021-11-02 2023-05-11 University Of Rochester Tcf7l2 mediated remyelination in the brain
CN118679180A (zh) * 2021-11-15 2024-09-20 阿奇利克斯股份有限公司 包含d结构域的多肽及其用途
CA3253069A1 (en) * 2022-05-31 2023-12-07 Oncopeptides Innovation 1 Ab NEW POLYPEPTIDES
US20260151538A1 (en) 2022-10-26 2026-06-04 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
KR20250129817A (ko) * 2022-11-29 2025-08-29 아르셀엑스, 인크. D-도메인 함유 폴리펩티드 및 그의 용도
EP4658294A2 (en) 2023-02-02 2025-12-10 University of Rochester Competitive replacement of glial cells
CN115861303B (zh) * 2023-02-16 2023-04-28 四川大学 基于肺部ct图像的egfr基因突变检测方法和系统
KR20260024373A (ko) * 2023-05-05 2026-02-20 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 다중-수용체 자연 살해 세포
AU2024276506A1 (en) 2023-05-19 2026-01-15 Carsgen Life Sciences Co., Ltd. Immune effector cell and use thereof
EP4745159A1 (en) 2023-07-10 2026-05-20 Carsgen Life Sciences Co., Ltd. COMPOSITION FOR CELLULAR IMMUNOTHERAPY AND METHOD
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases
US20260108629A1 (en) * 2024-08-14 2026-04-23 Kite Pharma, Inc. Vectors for production of therapeutic constructs

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US7763258B2 (en) 1997-05-20 2010-07-27 The Trustees Of The University Of Pennsylvania Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins
ID26964A (id) 1998-02-19 2001-02-22 Xcyte Therapies Inc Komposisi dan metode untuk pengaturan pengaktifan limfosit
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
EP1054018B1 (en) 1999-05-18 2009-01-28 Dyax Corp. Fab fragment libraries and methods for their use
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
NZ523912A (en) 2000-07-31 2005-03-24 Biolex Inc Expression of biologically active polypeptides in duckweed
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2471551C (en) 2001-12-27 2014-09-30 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
CA2478294C (en) 2002-03-19 2013-09-03 Plant Research International B.V. Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants
EP1539966B1 (en) 2002-09-12 2010-06-30 Greenovation Biotech GmbH Protein production method
AU2003294912B2 (en) 2002-12-20 2009-06-04 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
WO2005044982A2 (en) 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
AU2004271200A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2007019376A2 (en) 2005-08-03 2007-02-15 Rq Bioscience, Inc. Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
GB0907251D0 (en) 2009-04-28 2009-06-10 Univ Leiden Coplymers
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2013246443B2 (en) * 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
WO2014138805A1 (en) 2013-03-14 2014-09-18 Csl Limited Anti il-3r alpha agents and uses thereof
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
GB201306634D0 (en) 2013-04-11 2013-05-29 Univ Bristol Cage-like particles
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US10201606B2 (en) 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
CN107429253B (zh) * 2014-12-05 2021-11-05 希望之城公司 Cs1靶向性嵌合抗原受体修饰的t细胞
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
SG11201708257UA (en) 2015-04-06 2017-11-29 Subdomain Llc De novo binding domain containing polypeptides and uses thereof
KR20160126340A (ko) * 2015-04-23 2016-11-02 삼성전자주식회사 3중-나선 다발 단백질 및 이의 용도
JP6901493B2 (ja) * 2015-11-13 2021-07-14 アメリカ合衆国 抗bcmaポリペプチド及びタンパク質
US20190365806A1 (en) 2016-11-02 2019-12-05 Universität Basel Immunologically discernible cell surface variants for use in cell therapy
CN107254447B (zh) 2017-06-01 2020-10-16 刘未斌 Anti AFP CAR-T细胞及其制备方法和应用
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
SI3710067T1 (sl) 2017-11-14 2026-01-30 Arcellx, Inc. Polipeptidi, ki vsebujejo D-domeno, in njihova uporaba
AU2018368431B2 (en) 2017-11-14 2024-03-21 Arcellx, Inc. Multifunctional immune cell therapies

Similar Documents

Publication Publication Date Title
JP7779944B2 (ja) Dドメイン含有ポリペプチドおよびその使用
US12421291B2 (en) D-domain containing polypeptides and uses thereof
US20240124605A1 (en) D-domain containing polypeptides and uses thereof
US20250353908A1 (en) D-domain containing polypeptides and uses thereof
HK40131438A (en) D-domain containing polypeptides and uses thereof
HK40034396B (en) D-domain containing polypeptides and uses thereof
HK40034396A (en) D-domain containing polypeptides and uses thereof
EA051278B1 (ru) Полипептиды, содержащие домен d, и их применение
BR122025000319A2 (pt) Uso de uma proteína, um receptor de antígeno quimérico (car), ou uma célula para a fabricação de medicamentos para o tratamento de câncer
EA043660B1 (ru) Полипептиды, содержащие домен d, и их применение